Padma Mangu, MD
Endocrinology, Diabetes & Metabolism · West Chester, OHNPI 1548200959
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,468 of the $23,909 with a category attached, or 77.2%. Novo Nordisk accounts for 82.0% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2021 at $11,059 and has fallen 94.0% since, to $668 in 2025.
Across 404 payments — averaging $59.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$20K
- Lilly USA, LLC$948
- Dexcom, Inc.$720
- AstraZeneca$655
- Boehringer Ingelheim$270
- Medtronic$247
- plus $1K from 27 others
Across 57 payments — averaging $2650.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$101K
- AstraZeneca$23K
- Akcea Therapeutics, Inc.$21K
- Novartis$5K
- Astrazeneca UK Limited$2K
What the payments were for
- Speaking & faculty fees$18,46877%
- Food & beverage$5,37622%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 105 | $19,602 |
| Lilly USA, LLC | 66 | $948 |
| Dexcom, Inc. | 90 | $720 |
| AstraZeneca(2 entities) | 29 | $655 |
| Boehringer Ingelheim | 15 | $270 |
| Medtronic(2 entities) | 14 | $247 |
| AbbVie | 12 | $209 |
| Insulet Corporation | 12 | $177 |
| Sanofi-aventis U.S. LLC | 9 | $168 |
| Abbott | 8 | $142 |
| Tandem Diabetes Care, Inc. | 6 | $109 |
| Cequr Corporation | 2 | $64 |
| Corcept Therapeutics | 3 | $64 |
| Amphastar Pharmaceuticals, Inc. | 3 | $60 |
| Amgen(2 entities) | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Sequel Med Tech, LLC | 1 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Radius Health, Inc. | 2 | $31 |
| BETA Bionics, Inc. | 2 | $31 |
| Antares Pharma, Inc. | 2 | $30 |
| Valeritas, Inc. | 2 | $28 |
| IBSA Pharma Inc. | 2 | $27 |
| Zealand Pharma US, Inc. | 2 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Lifescan, Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
| Mannkind Corporation | 1 | $16 |
| Chiesi USA, Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,909 in reported general payments places this provider in the 85th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 399 | $442,489 |
| Tresiba Flextouch U-200Insulin Degludec | 182 | $241,504 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 170 | $156,001 |
| JardianceEmpagliflozin | 160 | $150,930 |
| TrulicityDulaglutide | 108 | $138,659 |
| MounjaroTirzepatide | 96 | $123,890 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 25 | $104,329 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 144 | $102,820 |
| Humalog Kwikpen U-100Insulin Lispro | 281 | $80,288 |
| FarxigaDapagliflozin Propanediol | 78 | $77,488 |
| Tresiba Flextouch U-100Insulin Degludec | 123 | $54,757 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 51 | $28,654 |
| Novolog FlexpenInsulin Aspart | 147 | $28,137 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $27,795 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 204 | $22,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Fiasp | $19,602 | $475,355499 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $948 | $280,976316 claims |
| Boehringer IngelheimJardiance | $270 | $150,930160 claims |
| AstraZenecaFarxiga | $655 | $77,48878 claims |
| AbbVieSynthroid | $209 | $11,926189 claims |
| Sanofi-aventis U.S. LLCAdmelog | $168 | $8,94532 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $20 | $4,887709 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in West Chester
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Nelson WattsCincinnati$346K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
- Shawn PeavieCincinnati$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.